

Supplemental Figure 1. Comparison of host proteins contained in WT and $\Delta pp65ab$ virions. A) The total number of host proteins found in RhCMV WT and $\Delta pp65ab$ virions and the overlapping proteins found in both samples are shown. B) All peptides and proteins found in WT and $\Delta pp65ab$ virions as shown here separated into either host or viral proteins dependent on their origin. C) Host proteins with a minimum abundance of 0.25mol% of the total amount of host proteins were ranked by abundance into two groups, proteins that had significant abundance in WT virions and were not found in $\Delta pp65ab$ virions (upper panel) and host proteins that were found in both virions, but with at least two fold higher abundance in the WT. D) Similar to C), host proteins were ranked by abundance, but only proteins are shown that were either present in $\Delta pp65ab$ virions and not in the WT (upper panel) or host proteins that were found in both virions, but with at least two fold higher abundance in $\Delta pp65ab$.



Supplemental Figure 2. Δ pp65ab establishes primary and secondary infections and protects against super-infection with Δ US2-11.. A) Two RhCMV sero-negative male RM (RM1 and RM2) were infected s.c with 10⁷ PFU of Δ pp65ab at day 1. CD4⁺ (blue) and CD8⁺ (red) T-cell responses were monitored in broncho-alveolar lavages (BAL) by intracellular cytokine staining (ICCS) at the indicated days using overlapping peptides of pp65ab and IE1/2) On day 659 the two animals were inoculated s.c. with 10⁷ PFU of Δ US2-11gag (green dotted line) and the T cell response to SIVgag was measured in addition. Note the absence of a T cell response to SIVgag or pp65 and a lack of boosting of responses to IE1. C) On day 876, the two RM were inoculated with 10⁷ PFU of WTgag (black dotted line) and the T cell response was monitored by ICCS. Note the appearance of *de novo* responses to SIVgag and pp65 and a boosting of the T cell response to IE1. D) On day 1107 the two RM were inoculated with 10⁷ PFU of Δ pp65ab-rtn

(blue dotted line). Using overlapping 15mer peptides a *de novo* response to SIVrev/tat/nef was detectable indicating super-infection. Also note a boosting of the IE1 response but not of pp65 or SIVgag-specific responses.



Supplemental Figure 3. T cells induced by heterologous prime/boost vaccination with pp65b do not protect against super-infection with Δ US2-11. Three CMV-negative RM were vaccinated with 1mg of pND/pp65b and boosted with MVApp65b at 6 and 12 weeks after the initial vaccination (black). As controls three CMV-negative RM were vaccinated with the parental pND plasmid not expressing any antigen and boosted with WT MVA at 6 and 12 weeks after the initial vaccination (green). At 18 weeks after the initial DNA vaccination both groups of animals were challenged with 10⁷ PFU of Δ US2-11gag. The left two panels show the specific T-cell responses to pp65 whereas the right two panes show specific T-cell responses to SIV gag. T-cells were isolated from broncho-alveolar lavages (BAL).



Supplemental Figure 4. Pp65b-specific T cells induced in naïve RM after DNA prime and MVA boost vaccination show mostly effector memory (T_{EM}) phenotype at the time of RhCMV $\Delta U\Delta V$ challenge. T cells were isolated from peripheral blood drawn from the three RM described in Figure 6 (Supplemental Figure 3) at the times indicated above each dot plot. The memory phenotype of the total pp65b response was determined by flow cytometry using the cell surface markers CD28 and CCR7 as previously described (1).

1. Hansen, S.G., Vieville, C., Whizin, N., Coyne-Johnson, L., Siess, D.C., Drummond, D.D., Legasse, A.W., Axthelm, M.K., Oswald, K., Trubey, C.M., et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. *Nature medicine* 15:293-299.